The key to finding a Psychiatry CRO or CNS CRO that can handle your clinical trials is choosing a partner with specialized knowledge and capabilities in your specialty. Vial, for instance, is a global Psychiatry CRO or CNS CRO that has mastered the complexities of complex clinical trials. Psychiatry CRO dedicated clinical development team has successfully managed some of the industry’s largest and most complex trials.
Vial CRO is a Psychiatry CRO with decades of experience and a strong reputation for delivering quality clinical trials. Established in 1992, this scientifically-driven company employs 2,500 professionals in 35 countries. Its clinical trials division specializes in neurology clinical research and has developed partnerships with sponsors and CROs that provide expertise in this field.
Vial CRO’s global infrastructure provides a comprehensive range of services for the conduct of clinical trials, from inception through post-analysis and report in brief. It has central labs, bio analytical labs, a phase I unit for first-in-man studies, and imaging and cardiovascular core labs.
The clinical trial services offered by Vial CRO are focused on helping clients develop breakthrough treatments and cure diseases. Its teams are comprised of medical experts with expertise in multiple therapeutic areas. The company leverages local regulatory expertise, deep therapeutic knowledge, and a high-science approach to develop and execute clinical trials.
Vial CRO’s team consists of physicians with extensive experience in psychiatry. The firm also offers clinical trial services to support the development of new drugs and devices. It also works with the pharmaceutical industry to facilitate global research, and helps to bring life-saving therapies to market. Its services span all phases of a drug’s development, including pre-clinical research, clinical trials, and regulatory approval.
Worldwide psychiatry CRO is a global research organization that builds strong relationships with clinicians worldwide to help them develop and conduct clinical trials. Their goal is to improve clinical trials by ensuring they are well designed and that they meet the needs of key stakeholders. By understanding the clinical trials industry, they can help you choose the best partners for your studies.
The Consortium’s members are pharmaceutical companies and charities that work together to develop new therapeutics for psychiatric diseases. They focus on identifying and validating new drug targets. Successful applicants will be provided with access to these organizations’ research expertise, project management expertise, and other relevant resources.
The organization’s Catalyst program, a global Phase I to IV contract research organization, will help its members participate in more psychiatric trials. Its goal is to increase patient focus, optimize study delivery, and drive enhanced customer efficiency. To this end, the network will connect 32 top clinical research sites.
Dr. Hans Moebius has extensive experience in psychiatry and clinical research, with particular expertise in neurology. He holds a PhD from the University of Heidelberg and is a member of the European College of Neuropsychopharmacology and the German Society of Neurology. He has also served as well as a member of the international working group for anti-dementia guidelines. Additionally, His experience also clinical research, in addition, regulatory affairs, and the pharmaceutical industry.
Before joining the INC Research team, Dr. Moebius served as well as Chief Scientific Officer at Merz Pharmaceuticals for five years, where he was responsible for leading the company’s strategic drug development efforts. His team helped establish the company’s CNS drug development pipeline and managed international drug development programs. He also served as well as the company’s senior vice president of global research and development and drug regulatory affairs. In addition, he received several professional distinctions, including the German Industry Innovation Award for his role in the development of meantime, a new CNS therapy for late-stage Alzheimer’s disease.
Read also: What Is a Clinical Research Organization?
CenExel CBH psychatry CRO is a research organization with extensive experience in the psychiatric field. The organization was formed in 2018 with the acquisition of ACMR and JBR Clinical Research. The companies specialize in research in pain, psychiatry, and central nervous system disorders. The company has an extensive network of research centers in the U.S., including two in New Jersey. Its mission is to help sponsors reduce costs by delivering high-quality trials on time.
CenExel CBH has a comprehensive clinical research infrastructure with over 100,000 square feet of facility space. Its management team has decades of experience in the field and a proven record of success. This centralized infrastructure allows for effective budgeting and contracting. The company’s team is led by a board-certified physician who has extensive experience in psychiatric clinical trials.
CenExel CBH psych psychiatry CRO is made up of three research facilities in the southeast U.S.: CBH Health in Atlanta, the Research Centers of America in Hollywood, Florida, and the Atlanta Center for Medical Research in Atlanta, Georgia. The company has a history of delivering clinical trials ranging from small-scale clinical trials to complex multinational trials. The company’s mission is to help pharmaceutical companies get their drugs to patients faster, safer, and more effective.
Five CNS CROs
A CNS CRO offers a comprehensive suite of services that help clients successfully move products through the critical post-discovery development phase and through the initial phase of human trials. With a global development and regulatory strategy, CNS ensures value at every stage of the product development life cycle. Additionally Its unique and innovative services include global regulatory and development support services.
Vial CRO is a CRO consortium with a focus on CNS and pain. With strong scientific interactions, flexible study plans and fast turnaround times, Vial CRO also offers a comprehensive array of services. We have the experience to deliver high-quality data to help accelerate the development of your new therapeutics.
We are proud members of Biocom California, the largest life sciences association in the state of California. Biocom California helps members connect with each other and with key decision makers in the life science community. Our strong ties to the California life sciences industry benefit us greatly. Additionally, Vial CRO is a proud member of the French American Chamber of Commerce in San Diego. Our membership benefits us with an extensive network of French and American business professionals.
Naason Science is a new CNS CRO with deep expertise and deep experience in drug development. Its capabilities span functional neuro-pharmacology readouts and in vitro and in vivo CNS Electrophysiology, behavioral testing, and neuroimaging. Led by a talented college of scientists, it accelerates CNS and pain research programs. Its data-driven approach enables fast lead selection and validation of target engagement and MOA.
QPS is an award-winning CRO that provides discovery, preclinical, and clinical research services to biotechnology and pharmaceutical clients around the world. Founded in 1995, the company now has over 1100 employees and is located in the US, Europe, and India. QPS’s expertise includes Neuropharmacology, Translational Medicine, and Clinical Development. The company operates GLP-compliant and CLIA-certified laboratories and offers customized, turnkey services to clients in all stages of their research.
Additionally QPS’ clinical operations include single and multi-centre clinical trials, project planning, data analysis, medical writing, and regulatory affairs. The company’s recent merger with JSW should increase its research capabilities in neurodegenerative diseases. In addition to clinical research, QPS also provides preclinical services to pharmaceutical clients globally, including toxicology and translational medicine.
CenExel Clinical Research
The CenExel Clinical Research Network is an organization that spans 13 clinical sites in the U.S., specializing in neurology, pain, immunology, and sleep. The company’s goal is to accelerate the development of innovative therapies and decrease costs associated with clinical research.
The organization also works with contract research organizations to streamline the development process for innovative treatments and reduce timelines for new therapies. Founded in 2018, the CenExel network helps companies improve patient care by facilitating partnerships with pharmaceutical companies, contract research organizations, and other research facilities.
The CenExel Clinical Research in CNR strengthens CenExel’s central nervous system trial capabilities and expands the company’s site network. The center is led by board-certified psychiatrist Dr. Tom Shiovitz, who has 30 years of clinical research experience.
Novotech has recently acquired Clinical Network Services, a leading early to late-stage CRO based in Australia, New Zealand and the US. The move is part of Novotech’s expansion strategy in the Asia-Pacific region. The firm has 140 employees in these countries, and will continue to operate such as a separate unit, but will work closely with Novotech across the Asia-Pacific region.
The company recently announced that it is a finalist for the Clinical Partnership of the Year Award. This award recognizes exceptional work across the global clinical research enterprise. The ceremony will take place at the Hyatt Regency Boston, MA, and honor the companies that are leading the way in their fields.